COSMOS Pharmaceutical Corp

Cosmos Health repurchased an additional 215,000 common shares on the open market at an average price of about $0.325 per share. Under the up-to-$5 million program, a total of 4,355,000 shares have been acquired so far for approximately $901,000. The company intends to continue repurchases depending on market conditions until the program expires on December 31, 2026; an extension is possible. CEO Greg Siokas says the purchases are based on his view that the stock is undervalued relative to the company’s worth. » Más en de.investing.com

Cosmos Health repurchased 770,000 common shares on the open market at an average price of $0.1956 per share, bringing total repurchases to 3,420,000 shares for about $650,000 under a program of up to $5 million. The program runs through December 31, 2026, and permits purchases, among other things, under SEC rules 10b5-1 and 10b-18; the company said it will continue purchases depending on market conditions. CEO Greg Siokas said the move was driven by his view that the current price is below the platform’s intrinsic value; the stock is currently trading at $0.24. » Más en de.investing.com

Cosmos Health has launched a collagen-based skincare line developed in Korea and has been selling it in the US via a direct-to-consumer model for over a month. The company plans global expansion and a multi-brand strategy to diversify into higher-margin product categories. Financial headwinds such as a low gross margin (10.4%), high cash burn and substantial debt could hinder scaling of the new business, although the stock is currently trading below its fair value according to InvestingPro. » Más en de.investing.com

Cosmos Health reports that its subsidiary Cana Laboratories has signed a three-year contract manufacturing agreement with Verisfield. Cana will produce 1.3 million units per year of VASCLOR GEST (progesterone) 400 mg vaginal suppositories, 3.9 million units in total over the term, in packs of 15 suppositories. The agreement expands Cana’s contract manufacturing into women’s health and reproductive medicine and is intended to diversify the high-margin contract manufacturing segment and order book. At the same time, Cosmos Health remains under financial pressure: the stock is down about 55% year-to-date, the gross margin is around 10.4%, although revenue has risen by almost 30% over the past twelve months. » Más en de.investing.com

Cosmos Health said that on the scheduled record date 4,874,126 Series‑B warrants with an exercise price of $0.95 expired, representing about 38% of outstanding warrants. No new shares were issued as a result of the expiry, so there was no dilution for existing shareholders. The stock trades around $0.25, near its 52‑week low; market capitalization is $14.42 million and the debt ratio is 1.08. CEO Greg Siokas called the expiry an improvement to the capital structure; an analysis currently rates the stock as undervalued. » Más en de.investing.com